ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report
Revised

Case Report: Pancytopenia as an indicator for lysosomal storage disease (Gaucher's Disease)

[version 2; peer review: 1 approved, 1 approved with reservations]
PUBLISHED 10 Oct 2019
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Introduction: Lysosomal storage disorders are a rare group of diseases with genetic origin in which Gaucher Disease (GD) stands out as the most frequent. GD type 1 is the most common form of this condition, and patients with this pathology present with unexplained cytopenias, in addition to hepatosplenomegaly, bone involvement, and in other cases neurological disorders. A case of a patient is presented, whose results showed thrombocytopenia and leukopenia in addition to hepatosplenomegaly. In Ecuador, there are very few reported cases of this clinical entity, and information on this disease is very limited.
Case: We present a case of a patient diagnosed with GD, who presented with thrombocytopenia and leukopenia in addition to hepatosplenomegaly, with the aim of emphasizing the importance of early recognition of this pathology, especially in patients with unexplained cytopenia’s or hepatosplenomegaly’s. In suspicion of GD, enzymatic quantification of β-glucocerebrosidase was performed, showing its deficit in addition to alteration in the GBA gene. 
Conclusion: We believe that a high index of suspicion together with enzymatic and genetic testing are essential for an early specific diagnosis, which will allow the administration of timely treatment and avoid irreversible complications in order to reduce morbidity and improve the clinical aspects of the patient.

Keywords

Gaucher disease, lysosomal storage disorders, cytopenia, β-glucocerebrosidase.

Revised Amendments from Version 1

According to the Reviewers' observations we have polished the manuscript with special attention on: 

- Corrections of the substrate reduction therapy (SRT)
- Description of the characteristics if the Gaucher disease in Latin America
- Expanded information on the patent's values
- Provided the genotype
- Correction of “Glycolipid glucosylceramide into ceramide and glucose”
- Corrections of Gaucher's Disease (GD)
- Included the genetic mutations

We hope that these changes will improve readers' understanding.

To read any peer review reports and author responses for this article, follow the "read" links in the Open Peer Review table.

Introduction

Lysosomal deposit disorders constitute a rare group of recessive hereditary monogenic diseases, resulting from the abnormal accumulation of non-degraded material in the lysosomes of different cells of the organism, as a result of the total or partial functional loss of specific lysosomal enzymes or cofactors involved in the degradation of these materials; the resulting lysosomal dysfunction leads to cell dysfunction and clinical anomalies1. The most common lysosomal storage disease is Gaucher disease (GD), with an estimated frequency of 1:40.000 to 1:86.000 inhabitants in the general population, except for the Jewish Ashkenazi ethnic group were it is estimated to be 1:850 births2, characterized by the defective function of the catabolic β-glucocerebrosidase enzyme, which leads to an accumulation of glucocerebroside in the lysosomes of different cells3, causing pancytopenia, hepatosplenomegaly, bone involvement and, sometimes neurological alteration4. The phenotype is variable and there are three clinical subtypes, which are classified by the absence or presence and progression of neurological involvement: type 1 or non-neuropathic form; type 2, the acute neuropathic form of infantile onset; and type 3, the neuronopathic form of juvenile onset5.

In Ecuador, there are very few reported cases of this pathology, and information on this disease is very limited6. In symptomatic patients, GD is usually a progressive disease that, if left untreated, can cause irreversible organ damage, severe morbidity, reduced quality of life and even premature death7.

Despite the availability of accurate and minimally invasive diagnostic tests, patients are often misdiagnosed as a result of the lack of experience with GD and the prolonged delay in accurate diagnosis, and this is likely to be translated into relative rarity of this disease8. Therefore, greater knowledge of the clinical and demographic characteristics of this clinical entity can improve early recognition, reduce the rate of inaccurate or delayed diagnoses for patients with GD, allowing timely treatment aimed at reducing morbidity and preventing irreversible sequels6.

Description of the case

A 29-year-old housewife from Loja-Ecuador, of mixed ethnicity, with no relevant family or personal history, presented to the outpatient service of the Isidro Ayora General Hospital, Loja, Ecuador. She presented with a pulsating holocraneal headache of slight intensity. Concomitantly, she presented with heartburn which responded positively to self-medication with omeprazole; additionally, she mentioned she was experiencing progressive loss of weight, fatigue and pain in the lower limbs and hands. Physical examination showed ecchymosis and petechiae scattered throughout the body. In the abdomen, hepatosplenomegaly was palpable. Routine laboratory results are summed up in the table below (Table 1).

Table 1. Laboratory results of patient’s parameters and their normal range.

Patient's parametresNormal range
Leukocytes (White blood
cell)
3400 mm34.500 – 11.000 mm3
Neutrophils1.9 K/uL2.0 – 8.0 K/uL
Lymphocytes1.5 K/uL1.0 – 5.1 K/uL
Red blood cell4.3 K/uL4.0 – 11.0 K/uL
Hemoglobin12.5 g/dL12.1 – 15.1 g/dL
Hematocrit38%36.1% – 44.3%
Platelet59 K/uL150 – 400 k/uL
PCR (C-Reactive Protein
(CRP))
16.1mg/L0.0 – 3.0 mg/L
VSG (erythrocyte
sedimentation rate (ESR)
33 mm/h0 to < 20 mm/h
Total bilirubins3 mg/dL0.3 – 1.0 mg/dL
BD (Direct bilirrubin)0.48 mg/dL0.0 – 0.3 mg/dL
BI (Inderect bilirrubin)2.52 mg/dL0.1 – 0.5 mg/dL

Viral serology tests for hepatitis B, C and human immunodeficiency virus were negative. An ultrasound of the upper abdomen was performed, where there was evidence of a distended liver without occupant injuries and splenomegaly [Figure 1]. Hepatosplenomegaly was observed in the CT-Scan in addition to incipient degenerative osteoarthritis at the dorsal spine. It was decided to perform a bone marrow biopsy, demonstrating abundant cells between the bone trabeculae, consisting of hematopoietic tissue, with a marked decrease in megakaryocytes of hypolobular nuclei, and myeloid-erythroid relationship conserved. In the inter and paratrabecular spaces, abundant clusters of macrophages of the typical broad cytoplasm are observed like “crumpled paper” with small, regular nuclei displaced to the periphery [Figure 2]. The morphological picture is suggestive of lysosomal storage disease, and with the suspicion of GD, quantification of the enzymatic activity of β-glucocerebrosidase was performed, confirming its deficit with a result of 0.27 µmol/L/h (normal range: 2.3 – 12 nmol/h/Ml). Sequential analysis of the GBA gene showed the presence of an apparently homozygous pathogenic alteration in the GBA gene (Nucleotide change: c.1226A>G; Amino acid change: G p.Asn409Ser).

20fd7f1b-7fde-48f6-8e5f-5eab58ef11f1_figure1.gif

Figure 1. Upper abdomen ultrasonography where hepatosplenomegaly is observed.

20fd7f1b-7fde-48f6-8e5f-5eab58ef11f1_figure2.gif

Figure 2. Bone marrow biopsy: Cuts show bony trabeculae, including extensive medullary replacement by histiocytic reticulum-like cells, with eosinophilic, pale cytoplasm and eccentric nuclei, some cells have a vacuolated cytoplasm with folded appearance on crumpled paper.

Unfortunately, enzymatic replacement or substrate reduction therapy are not available in our Hospital. At the time of writing the patient is regularly monitored at the Isidro Ayora General Hospital, Loja until the enzymatic medication can be obtained. Currently, the patient persists in good general conditions, without worsening clinical condition. It should be mentioned that she continues with bicytopenia and hepatosplenomegaly, her conditions are expected to be remit once the enzymatic treatment has been administered.

Discussion

This clinical case is a representative example of the clinical, biochemical and genetic characteristics of GD type 19, characterized by the variability in the signs, symptoms, severity and progression of the disease10. The most common signs and symptoms are: splenomegaly [95%], hepatomegaly [87%], radiological bone disease [81%], thrombocytopenia [50%], anemia [40%], bone pain [27%]11.

GD is caused by mutations in the GBA gene, located on chromosome 1 (1q21), leading to markedly decreased activity of the lysosomal enzyme, β-glucocerebrosidase, which hydrolyzes the glycolipid glucocerebroside into ceramide and glucose12. In the case studied, it was possible to observe a decrease in the enzymatic activity of β-glucocerebrosidase, in addition to alteration of the gene GBA. The consequence of this deficiency is attributed to the accumulation of glucosilcerebroside in macrophages, inducing its transformation in Gaucher cells, which under optical microscopy are usually presented as enlarged cells with eccentric nuclei and condensed chromatin and cytoplasm with heterogeneous appearance as “crumpled paper”13, similar characteristics to the bone marrow biopsy performed in our patient. However, the presence of this type of histological pattern has occasionally been described in several hematological malignancies14 In our patient, the basic aspects that guided the diagnosis of GD were the finding of a bicitopenia in a routine laboratory examination, in addition to the presence of unexplained hepatosplenomegaly. Determining the enzymatic activity of reduced β-glucocerebrosidase or absence is therefore the gold standard for the diagnosis of all GD variants. In the present study a clearly reduced activity of this enzyme was evident, in addition to an apparently homozygous pathogenic alteration of the GBA gene (Nucleotide change: c.1226A>G; Amino acid change: G p.Asn409Ser), allowing us to establish a definitive diagnosis of GD.

Without considering the GD in the differential diagnosis of the patient with this type of symptomatology, the definitive diagnosis can be missed or delayed, because the signs and symptoms frequent other more common conditions, including the malignant neoplasms of hematological origin15. Therefore, it is essential to strengthen the knowledge about GD, allowing to reduce the threshold for diagnostic tests and reduce the rate of erroneous diagnoses, in addition to promoting the earliest start of treatment when it is indicated.

Conclusion

GD should be considered in the differential diagnosis of patients with unexplained pancytopenia or hepatosplenomegaly. A high index of suspicion together with enzymatic and genetic testing are essential for an early specific diagnosis, which will allow the administration of timely treatment and avoid irreversible complications in order to reduce morbidity and improve the clinical aspects of the patient.

Consent

Written informed consent for publication of their clinical details and clinical images was obtained from the patient.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 29 May 2019
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Ortega-Rosales A, Burneo-Rosales C, Romero-Ulloa G and Burneo-Rosales G. Case Report: Pancytopenia as an indicator for lysosomal storage disease (Gaucher's Disease) [version 2; peer review: 1 approved, 1 approved with reservations]. F1000Research 2019, 8:755 (https://doi.org/10.12688/f1000research.18802.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 2
VERSION 2
PUBLISHED 10 Oct 2019
Revised
Views
19
Cite
Reviewer Report 17 Dec 2019
Neal J. Weinreb, University of Miami Miller School of Medicine, Department of Human Genetics and Medicine (Hematology), UHealth Sylvester Coral Springs, Coral Springs, FL, USA 
Approved with Reservations
VIEWS 19
I have attached my suggested revised text here and here, I think that would be a lot easier for both the journal and the authors.

After reading the revised version, I still had the same concerns raised ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Weinreb NJ. Reviewer Report For: Case Report: Pancytopenia as an indicator for lysosomal storage disease (Gaucher's Disease) [version 2; peer review: 1 approved, 1 approved with reservations]. F1000Research 2019, 8:755 (https://doi.org/10.5256/f1000research.22690.r57304)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
9
Cite
Reviewer Report 04 Nov 2019
Ellen Sidransky, Section on Molecular Neurogenetics MGB, National Human Genome Research Institute, Bethesda, MD, 20894-3708, USA 
Approved
VIEWS 9
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Sidransky E. Reviewer Report For: Case Report: Pancytopenia as an indicator for lysosomal storage disease (Gaucher's Disease) [version 2; peer review: 1 approved, 1 approved with reservations]. F1000Research 2019, 8:755 (https://doi.org/10.5256/f1000research.22690.r54937)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 29 May 2019
Views
18
Cite
Reviewer Report 09 Jul 2019
Ellen Sidransky, Section on Molecular Neurogenetics MGB, National Human Genome Research Institute, Bethesda, MD, 20894-3708, USA 
Approved with Reservations
VIEWS 18
While this case does not report any new information, it fulfills an important role in highlighting rare disease cases worldwide, raising awareness and further informing health care practitioners. However there are several errors that must be corrected.
 
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Sidransky E. Reviewer Report For: Case Report: Pancytopenia as an indicator for lysosomal storage disease (Gaucher's Disease) [version 2; peer review: 1 approved, 1 approved with reservations]. F1000Research 2019, 8:755 (https://doi.org/10.5256/f1000research.20597.r50548)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 29 May 2019
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.